Skip to content
Companies

Embold Therapeutics

Engineered enzyme therapy for genetic Parkinson's disease

Raised to date

$2.5M

of $5M offered across 1 Form D filing

Still open
$2.5M
Investors
7
Last filed
Jul 24, 2026

About

Embold Therapeutics is a Redwood City, California biotech developing disease-modifying treatments for genetically driven neurodegeneration, with an initial focus on Parkinson's disease. The company engineers optimized variants of human enzymes to overcome the instability and poor efficacy of the natural versions, and pairs them with a CNS delivery system. Its lead program, EMB-0141, targets glucocerebrosidase (GCase) deficiency in GBA-associated Parkinson's disease, which affects roughly 5-15% of PD patients. The company was incorporated in February 2023 and is led by founder and CEO Gjalt W. Huisman, PhD, previously a long-time enzyme-engineering leader at Codexis.

Embold applies protein engineering and synthetic biology — rather than small molecules or gene therapy — to build engineered human enzyme variants that fix the stability and half-life problems of the natural enzyme, coupled with a proprietary CNS delivery technology that gets them across into the brain.

Funding

  • Security to be acquiredFiled Jul 24, 2026Form D/A
    $2.5M/ $5M

Product

EMB-0141

Preclinical enzyme therapeutic

Lead preclinical program: an engineered glucocerebrosidase (GCase) variant for GBA-associated Parkinson's disease, designed to overcome the instability and poor serum half-life of natural human GCase.

  • Engineered GCase variant with improved stability over the natural human enzyme
  • Improved serum half-life relative to natural GCase
  • Targets GBA-associated Parkinson's disease, roughly 5-15% of all PD patients

Built for

Patients with genetically driven neurodegeneration — initially GBA-associated Parkinson's disease — reached through neurologists, movement-disorder centers, and pharmaceutical partners

People on file